Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).

Abstract

BACKGROUND:

A one-tablet, once-daily abacavir/lamivudine fixed-dose combination (FDC) has been recently approved to treat HIV-1 infection.

METHODS:

A randomized, open-label, parallel-group, multicenter study to compare the efficacy and safety of the FDC group to the separate entities (SE) group, in combination with tenofovir and a new protease inhibitor or nonnucleoside reverse transcription inhibitor in antiretroviral-experienced adults experiencing virologic failure (VF). Eligible subjects had viral loads >1000 copies/mL with < or =3 nucleoside reverse transcription inhibitor-associated mutations. The primary efficacy end point was time-average changed from baseline (average area under the curve minus baseline) in plasma HIV-1 RNA over 48 weeks.

RESULTS:

A total of 186 subjects were enrolled. The average area under the curve minus baseline was -1.65 and -1.83 log10 copies/mL in the FDC and SE groups, respectively (intention to treat; 95% confidence interval: -0.13, 0.38). Patients in the FDC (50%) and SE groups (47%) achieved viral loads <50 copies/mL based on the time to loss of virologic response algorithm. VF was low and similar in both groups (FDC, 16%; SE, 18%). Tolerability was similar between the 2 groups.

CONCLUSIONS:

The FDC group had noninferior efficacy over 48 weeks to the SE group in treatment-experienced subjects with VF.

• Authors: Anthony Lamarca, Nathan Clumeck, Andreas Plettenberg, Pere Domingo, Kaisong Fu, Charles Craig, Henry Zhao, Maria Watson, David Gordon, Trevor Scott
• Journal: Journal of acquired immune deficiency syndromes (1999) (J Acquir Immune Defic Syndr) Vol. 41 Issue 5 Pg. 598-606 (Apr 15 2006) ISSN: 1525-4135 [Print] United States
• PMID: 16652033 (Publication Type: Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Anti-HIV Agents
• Dideoxynucleosides
• Lamivudine
• abacavir

Topics

• Adult
• Aged
• Anti-HIV Agents (administration & dosage, therapeutic use)
• Dideoxynucleosides (administration & dosage, therapeutic use)
• Drug Administration Schedule
• Drug Therapy, Combination
• Female
• HIV Infections (drug therapy)
• HIV-1
• Humans
• Lamivudine (administration & dosage, therapeutic use)
• Male
• Middle Aged
• Safety